BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 34446858)

  • 1. CCT245718, a dual FLT3/Aurora A inhibitor overcomes D835Y-mediated resistance to FLT3 inhibitors in acute myeloid leukaemia cells.
    Tariq MU; Furqan M; Parveen H; Ullah R; Muddassar M; Saleem RSZ; Bavetsias V; Linardopoulos S; Faisal A
    Br J Cancer; 2021 Sep; 125(7):966-974. PubMed ID: 34446858
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns.
    Moore AS; Faisal A; Gonzalez de Castro D; Bavetsias V; Sun C; Atrash B; Valenti M; de Haven Brandon A; Avery S; Mair D; Mirabella F; Swansbury J; Pearson AD; Workman P; Blagg J; Raynaud FI; Eccles SA; Linardopoulos S
    Leukemia; 2012 Jul; 26(7):1462-70. PubMed ID: 22354205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A dual inhibitor overcomes drug-resistant FLT3-ITD acute myeloid leukemia.
    Wang P; Xiao X; Zhang Y; Zhang B; Li D; Liu M; Xie X; Liu C; Liu P; Ren R
    J Hematol Oncol; 2021 Jul; 14(1):105. PubMed ID: 34217323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Internal tandem duplication mutations in the tyrosine kinase domain of FLT3 display a higher oncogenic potential than the activation loop D835Y mutation.
    Marhäll A; Heidel F; Fischer T; Rönnstrand L
    Ann Hematol; 2018 May; 97(5):773-780. PubMed ID: 29372308
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Natural and Semisynthetic Chalcones as Dual FLT3 and Microtubule Polymerization Inhibitors.
    Malik HS; Bilal A; Ullah R; Iqbal M; Khan S; Ahmed I; Krohn K; Saleem RSZ; Hussain H; Faisal A
    J Nat Prod; 2020 Oct; 83(10):3111-3121. PubMed ID: 32975953
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ponatinib may overcome resistance of FLT3-ITD harbouring additional point mutations, notably the previously refractory F691I mutation.
    Zirm E; Spies-Weisshart B; Heidel F; Schnetzke U; Böhmer FD; Hochhaus A; Fischer T; Scholl S
    Br J Haematol; 2012 May; 157(4):483-92. PubMed ID: 22409268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Crenolanib is active against models of drug-resistant FLT3-ITD-positive acute myeloid leukemia.
    Zimmerman EI; Turner DC; Buaboonnam J; Hu S; Orwick S; Roberts MS; Janke LJ; Ramachandran A; Stewart CF; Inaba H; Baker SD
    Blood; 2013 Nov; 122(22):3607-15. PubMed ID: 24046014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
    Bavetsias V; Crumpler S; Sun C; Avery S; Atrash B; Faisal A; Moore AS; Kosmopoulou M; Brown N; Sheldrake PW; Bush K; Henley A; Box G; Valenti M; de Haven Brandon A; Raynaud FI; Workman P; Eccles SA; Bayliss R; Linardopoulos S; Blagg J
    J Med Chem; 2012 Oct; 55(20):8721-34. PubMed ID: 23043539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of acquired drug resistance in FLT3-mutated acute myeloid leukemia cells via distinct drug combination strategies.
    Zhang W; Gao C; Konopleva M; Chen Y; Jacamo RO; Borthakur G; Cortes JE; Ravandi F; Ramachandran A; Andreeff M
    Clin Cancer Res; 2014 May; 20(9):2363-74. PubMed ID: 24619500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CDC25A governs proliferation and differentiation of FLT3-ITD acute myeloid leukemia.
    Bertoli S; Boutzen H; David L; Larrue C; Vergez F; Fernandez-Vidal A; Yuan L; Hospital MA; Tamburini J; Demur C; Delabesse E; Saland E; Sarry JE; Galcera MO; Mansat-De Mas V; Didier C; Dozier C; Récher C; Manenti S
    Oncotarget; 2015 Nov; 6(35):38061-78. PubMed ID: 26515730
    [TBL] [Abstract][Full Text] [Related]  

  • 11. G-749, a novel FLT3 kinase inhibitor, can overcome drug resistance for the treatment of acute myeloid leukemia.
    Lee HK; Kim HW; Lee IY; Lee J; Lee J; Jung DS; Lee SY; Park SH; Hwang H; Choi JS; Kim JH; Kim SW; Kim JK; Cools J; Koh JS; Song HJ
    Blood; 2014 Apr; 123(14):2209-19. PubMed ID: 24532805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistance.
    Patel RK; Weir MC; Shen K; Snyder D; Cooper VS; Smithgall TE
    PLoS One; 2019; 14(12):e0225887. PubMed ID: 31790499
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dual FLT3/TOPK inhibitor with activity against FLT3-ITD secondary mutations potently inhibits acute myeloid leukemia cell lines.
    Dayal N; Opoku-Temeng C; Hernandez DE; Sooreshjani MA; Carter-Cooper BA; Lapidus RG; Sintim HO
    Future Med Chem; 2018 Apr; 10(7):823-835. PubMed ID: 29437468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sensitivity toward sorafenib and sunitinib varies between different activating and drug-resistant FLT3-ITD mutations.
    Kancha RK; Grundler R; Peschel C; Duyster J
    Exp Hematol; 2007 Oct; 35(10):1522-6. PubMed ID: 17889720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of PI3Kδ and FLT3 signaling exerts synergistic antitumor activity and overcomes acquired drug resistance in FLT3-activated acute myeloid leukemia.
    He Y; Sun L; Xu Y; Fu L; Li Y; Bao X; Fu H; Xie C; Lou L
    Cancer Lett; 2018 Apr; 420():49-59. PubMed ID: 29409989
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discovery of indirubin-3'-aminooxy-acetamide derivatives as potent and selective FLT3/D835Y mutant kinase inhibitors for acute myeloid leukemia.
    Lee JH; Shin JE; Kim W; Jeong P; Kim MJ; Oh SJ; Lee HJ; Park HW; Han SY; Kim YC
    Eur J Med Chem; 2022 Jul; 237():114356. PubMed ID: 35489222
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FLT3-ITD confers resistance to the PI3K/Akt pathway inhibitors by protecting the mTOR/4EBP1/Mcl-1 pathway through STAT5 activation in acute myeloid leukemia.
    Nogami A; Oshikawa G; Okada K; Fukutake S; Umezawa Y; Nagao T; Kurosu T; Miura O
    Oncotarget; 2015 Apr; 6(11):9189-205. PubMed ID: 25826077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Vulnerabilities in
    Uras IZ; Maurer B; Nebenfuehr S; Zojer M; Valent P; Sexl V
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544932
    [TBL] [Abstract][Full Text] [Related]  

  • 19. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
    Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
    Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of imidazo[1,2-a]pyridine-thiophene derivatives as FLT3 and FLT3 mutants inhibitors for acute myeloid leukemia through structure-based optimization of an NEK2 inhibitor.
    Zhang L; Lakkaniga NR; Bharate JB; Mcconnell N; Wang X; Kharbanda A; Leung YK; Frett B; Shah NP; Li HY
    Eur J Med Chem; 2021 Dec; 225():113776. PubMed ID: 34479037
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.